CHANGING THE WAY PATHOLOGISTS SEE CANCER
CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective.
|
CS-Keys is developing products to aid in the detection of breast cancer at its earliest stages including in conditions such as DCIS.
 |
Barrett's esophagus may be a precursor to cancer in some patients. CS-Keys may help physicians identify patients at greatest risk.
 |
CS-Keys technology appears to apply well to the following:
 |